A detailed history of Northern Trust Corp transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Northern Trust Corp holds 1,860,925 shares of BCRX stock, worth $14.3 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,860,925
Previous 1,754,763 6.05%
Holding current value
$14.3 Million
Previous $10.8 Million 30.42%
% of portfolio
0.0%
Previous 0.0%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$6.41 - $8.69 $680,498 - $922,547
106,162 Added 6.05%
1,860,925 $14.1 Million
Q2 2024

Aug 14, 2024

SELL
$4.13 - $6.79 $208,201 - $342,297
-50,412 Reduced 2.79%
1,754,763 $10.8 Million
Q1 2024

May 14, 2024

SELL
$4.89 - $7.65 $203,379 - $318,171
-41,591 Reduced 2.25%
1,805,175 $9.17 Million
Q4 2023

Feb 13, 2024

SELL
$4.98 - $6.77 $29,367 - $39,922
-5,897 Reduced 0.32%
1,846,766 $11.1 Million
Q3 2023

Nov 13, 2023

BUY
$6.71 - $7.92 $101,602 - $119,924
15,142 Added 0.82%
1,852,663 $13.1 Million
Q2 2023

Aug 11, 2023

BUY
$6.96 - $8.81 $517,977 - $655,657
74,422 Added 4.22%
1,837,521 $12.9 Million
Q1 2023

May 15, 2023

BUY
$7.94 - $11.84 $124,173 - $185,165
15,639 Added 0.89%
1,763,099 $14.7 Million
Q4 2022

Feb 13, 2023

SELL
$10.5 - $14.2 $517,975 - $700,500
-49,331 Reduced 2.75%
1,747,460 $20.1 Million
Q3 2022

Nov 14, 2022

SELL
$10.79 - $14.81 $216,803 - $297,577
-20,093 Reduced 1.11%
1,796,791 $22.6 Million
Q2 2022

Aug 12, 2022

BUY
$7.89 - $17.88 $134,019 - $303,709
16,986 Added 0.94%
1,816,884 $19.2 Million
Q1 2022

May 13, 2022

SELL
$11.56 - $19.76 $706,431 - $1.21 Million
-61,110 Reduced 3.28%
1,799,898 $29.3 Million
Q4 2021

Feb 08, 2022

SELL
$11.18 - $15.46 $6.45 Million - $8.91 Million
-576,576 Reduced 23.65%
1,861,008 $25.8 Million
Q3 2021

Nov 15, 2021

SELL
$14.21 - $17.65 $322,964 - $401,149
-22,728 Reduced 0.92%
2,437,584 $35 Million
Q2 2021

Aug 13, 2021

BUY
$9.5 - $17.24 $4.83 Million - $8.76 Million
508,184 Added 26.03%
2,460,312 $38.9 Million
Q1 2021

May 12, 2021

SELL
$7.37 - $13.61 $817,915 - $1.51 Million
-110,979 Reduced 5.38%
1,952,128 $19.9 Million
Q4 2020

Feb 11, 2021

SELL
$3.37 - $8.61 $92,065 - $235,216
-27,319 Reduced 1.31%
2,063,107 $15.4 Million
Q3 2020

Nov 16, 2020

BUY
$3.43 - $5.53 $556,346 - $896,966
162,200 Added 8.41%
2,090,426 $7.18 Million
Q2 2020

Aug 14, 2020

BUY
$1.9 - $5.61 $112,282 - $331,528
59,096 Added 3.16%
1,928,226 $9.19 Million
Q1 2020

May 14, 2020

BUY
$1.6 - $4.11 $61,916 - $159,048
38,698 Added 2.11%
1,869,130 $3.74 Million
Q4 2019

Feb 14, 2020

BUY
$1.59 - $3.45 $735,581 - $1.6 Million
462,630 Added 33.82%
1,830,432 $6.32 Million
Q3 2019

Nov 13, 2019

BUY
$2.5 - $3.73 $11,882 - $17,728
4,753 Added 0.35%
1,367,802 $3.92 Million
Q2 2019

Aug 13, 2019

BUY
$2.91 - $9.15 $6,154 - $19,352
2,115 Added 0.16%
1,363,049 $5.17 Million
Q1 2019

May 13, 2019

BUY
$7.38 - $9.72 $76,146 - $100,290
10,318 Added 0.76%
1,360,934 $11.1 Million
Q4 2018

Feb 12, 2019

SELL
$6.51 - $9.6 $20,942 - $30,883
-3,217 Reduced 0.24%
1,350,616 $10.9 Million
Q3 2018

Nov 14, 2018

BUY
$5.52 - $7.99 $768,781 - $1.11 Million
139,272 Added 11.47%
1,353,833 $10.3 Million
Q2 2018

Sep 18, 2018

SELL
$4.6 - $6.52 $28,933 - $41,010
-6,290 Reduced 0.52%
1,214,561 $6.96 Million
Q2 2018

Aug 14, 2018

BUY
$4.6 - $6.52 $147,085 - $208,477
31,975 Added 2.69%
1,220,851 $7 Million
Q1 2018

May 09, 2018

BUY
$4.35 - $5.82 $56,741 - $75,916
13,044 Added 1.11%
1,188,876 $5.67 Million
Q4 2017

Feb 14, 2018

BUY
$4.16 - $5.33 $686,221 - $879,220
164,957 Added 16.32%
1,175,832 $5.77 Million
Q3 2017

Nov 13, 2017

BUY
$4.1 - $5.97 $4.14 Million - $6.03 Million
1,010,875
1,010,875 $5.3 Million

Others Institutions Holding BCRX

About BIOCRYST PHARMACEUTICALS INC


  • Ticker BCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,944,992
  • Market Cap $1.43B
  • Description
  • BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...
More about BCRX
Track This Portfolio

Track Northern Trust Corp Portfolio

Follow Northern Trust Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.